JP2012512815A5 - - Google Patents

Download PDF

Info

Publication number
JP2012512815A5
JP2012512815A5 JP2011541030A JP2011541030A JP2012512815A5 JP 2012512815 A5 JP2012512815 A5 JP 2012512815A5 JP 2011541030 A JP2011541030 A JP 2011541030A JP 2011541030 A JP2011541030 A JP 2011541030A JP 2012512815 A5 JP2012512815 A5 JP 2012512815A5
Authority
JP
Japan
Prior art keywords
pharmaceutical composition
antagonist
composition according
subject
csf
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2011541030A
Other languages
English (en)
Japanese (ja)
Other versions
JP5727379B2 (ja
JP2012512815A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/AU2009/001672 external-priority patent/WO2010071924A1/en
Publication of JP2012512815A publication Critical patent/JP2012512815A/ja
Publication of JP2012512815A5 publication Critical patent/JP2012512815A5/ja
Application granted granted Critical
Publication of JP5727379B2 publication Critical patent/JP5727379B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2011541030A 2008-12-22 2009-12-21 変形性関節症の治療 Active JP5727379B2 (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US13967908P 2008-12-22 2008-12-22
US61/139,679 2008-12-22
US16448609P 2009-03-30 2009-03-30
US61/164,486 2009-03-30
PCT/AU2009/001672 WO2010071924A1 (en) 2008-12-22 2009-12-21 Osteoarthritis treatment

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2015031198A Division JP2015143233A (ja) 2008-12-22 2015-02-20 変形性関節症の治療

Publications (3)

Publication Number Publication Date
JP2012512815A JP2012512815A (ja) 2012-06-07
JP2012512815A5 true JP2012512815A5 (OSRAM) 2013-02-14
JP5727379B2 JP5727379B2 (ja) 2015-06-03

Family

ID=42286786

Family Applications (3)

Application Number Title Priority Date Filing Date
JP2011541030A Active JP5727379B2 (ja) 2008-12-22 2009-12-21 変形性関節症の治療
JP2015031198A Pending JP2015143233A (ja) 2008-12-22 2015-02-20 変形性関節症の治療
JP2017114806A Active JP6458086B2 (ja) 2008-12-22 2017-06-12 変形性関節症の治療

Family Applications After (2)

Application Number Title Priority Date Filing Date
JP2015031198A Pending JP2015143233A (ja) 2008-12-22 2015-02-20 変形性関節症の治療
JP2017114806A Active JP6458086B2 (ja) 2008-12-22 2017-06-12 変形性関節症の治療

Country Status (19)

Country Link
US (4) US9243061B2 (OSRAM)
EP (2) EP3056217B1 (OSRAM)
JP (3) JP5727379B2 (OSRAM)
KR (2) KR101898982B1 (OSRAM)
CN (2) CN106397591A (OSRAM)
AU (1) AU2009329814B2 (OSRAM)
BR (1) BRPI0918356B1 (OSRAM)
CA (1) CA2746827C (OSRAM)
CY (1) CY1117698T1 (OSRAM)
DK (1) DK2376121T4 (OSRAM)
ES (2) ES2572368T5 (OSRAM)
HK (1) HK1226938A1 (OSRAM)
HR (1) HRP20160577T4 (OSRAM)
HU (1) HUE028615T2 (OSRAM)
PL (1) PL2376121T5 (OSRAM)
RU (2) RU2011127334A (OSRAM)
SI (2) SI2376121T1 (OSRAM)
SM (1) SMT201600156B (OSRAM)
WO (1) WO2010071924A1 (OSRAM)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3056217B1 (en) 2008-12-22 2021-06-30 The University of Melbourne Osteoarthritis treatment
KR101761324B1 (ko) 2008-12-22 2017-07-25 더 유니버시티 오브 멜버른 통증 치료
KR20150056846A (ko) 2012-09-20 2015-05-27 모르포시스 아게 류마티스 관절염에 대한 치료
DE102013222200A1 (de) * 2013-10-31 2015-08-27 Osram Opto Semiconductors Gmbh Elektronisches Bauelement und Verfahren zum Herstellen eines elektronischen Bauelements
KR20200054171A (ko) * 2017-08-14 2020-05-19 지네르바 파마슈티컬스, 인코포레이티드 경피 칸나비디올 겔을 이용한 골관절염의 치료 방법
WO2020104833A1 (en) * 2018-11-19 2020-05-28 4P-Pharma Composition and methods for regulating chondrocyte proliferation and increasing of cartilage matrix production
CN110075304B (zh) * 2019-05-29 2020-02-11 四川大学华西医院 一种治疗骨关节炎的药物组合物及其用途

Family Cites Families (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5225539A (en) * 1986-03-27 1993-07-06 Medical Research Council Recombinant altered antibodies and methods of making altered antibodies
AU630496B2 (en) 1989-07-14 1992-10-29 Schering Corporation Antagonists of gm-csf derived from the carboxyl terminus
EP0486572B1 (en) 1989-08-11 1998-01-07 Amrad Corporation Limited Improvements in granulocyte-macrophage colony-stimulating factor receptor and derivatives thereof
US5747032A (en) 1990-08-10 1998-05-05 Amrad Corporation Limited Monoclonal antibody to human granulocyte macrophage colony stimulating factor
WO1994011404A1 (en) 1992-11-19 1994-05-26 Dana-Farber Cancer Institute Antibodies for gm-csf receptor and uses thereof
ES2176484T3 (es) 1995-08-18 2002-12-01 Morphosys Ag Bancos de proteinas/(poli)peptidos.
AUPP525198A0 (en) 1998-08-13 1998-09-03 Medvet Science Pty. Ltd. Monoclonal antibody inhibitor of GM-CSF, IL-3 and IL-5 and other cytokines and uses thereof
US7108852B2 (en) 2000-03-20 2006-09-19 Warner-Lambert Company Llc Methods of treating inflammation using antibodies to M-CSF
US7455836B2 (en) 2000-05-08 2008-11-25 The University Of Melbourne Method of treatment and agents useful for same
AU2002346882A1 (en) * 2001-10-26 2003-05-06 Novartis Ag Methods for the treatment of osteoarthritis and compositions thereof
ES2365606T3 (es) 2002-02-13 2011-10-07 Ludwig Institute For Cancer Research Ltd. Anticuerpos contra gm-csf quiméricos.
US20040241755A1 (en) * 2003-06-02 2004-12-02 Pfizer Inc. Human cell assay to determine effect of sample compounds on Col2 enhancer expression
ES2341461T5 (es) 2004-02-11 2014-10-29 Warner-Lambert Company Llc Procedimientos de tratamiento de la artrosis con anticuerpos ANTI-IL-6
JP4825667B2 (ja) * 2004-03-31 2011-11-30 一和 中尾 関節炎症治療剤又は予防剤
EP1593690B1 (en) 2004-05-05 2009-07-01 Micromet AG Preparation of ScFv antibody fragments
WO2006023412A2 (en) 2004-08-18 2006-03-02 The Government Of The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Biomarkers for osteoarthritis
US20060040258A1 (en) 2004-08-23 2006-02-23 Huiyan Guo Water-soluble conjugates and methods of preparation
EP1874819B1 (en) 2005-04-18 2015-05-27 Amgen Research (Munich) GmbH Antibody neutralizers of human granulocyte macrophage colony stimulating factor
HUE058876T2 (hu) * 2005-05-18 2022-09-28 Morphosys Ag Anti-GM-CSF antitestek és felhasználásuk
JP4736037B2 (ja) 2005-10-26 2011-07-27 株式会社イーベック ヒトｇｍ−ｃｓｆに結合するヒトのモノクローナル抗体並びにその抗原結合部分
CA2629850A1 (en) * 2005-12-01 2007-06-07 Domantis Limited Competitive domain antibody formats that bind interleukin 1 receptor type 1
ES2609088T3 (es) * 2006-02-08 2017-04-18 Morphotek, Inc. Péptidos GM-CSF antigénicos y anticuerpos anti-GM-CSF
RU2495050C2 (ru) * 2006-03-27 2013-10-10 Медимьюн Лимитед Связующий элемент для рецептора gm-csf
US7741273B2 (en) 2006-04-13 2010-06-22 Warsaw Orthopedic, Inc. Drug depot implant designs
US20080206241A1 (en) * 2006-11-21 2008-08-28 Kalobios Pharmaceuticals Inc. Methods of Treating Chronic Inflammatory Diseases Using a GM-CSF Antagonist
WO2008080134A2 (en) * 2006-12-22 2008-07-03 Rigel Pharmaceuticals, Inc. 4-amin0-2- (hetero) arylamino-5- (hetero) arylthiazoles useful as axl inhibitors
EP2160407A4 (en) * 2007-05-23 2011-07-27 Crc For Asthma And Airways Ltd NEUTRALIZING ANTIBODIES
TW200918553A (en) * 2007-09-18 2009-05-01 Amgen Inc Human GM-CSF antigen binding proteins
WO2009042854A1 (en) * 2007-09-26 2009-04-02 Musculoskeletal Research Llc Ion-channel regulator compositions and methods of using same
US20100297135A1 (en) 2007-11-12 2010-11-25 Crc For Asthma And Airways Ltd. Epitope for neutralizing antibodies
PT2215119E (pt) * 2007-11-13 2013-02-11 Boehringer Ingelheim Int Anticorpos monoclonais que se ligam a hgm-csf e composições médicas que os compreendem
EP2271671A2 (en) 2008-03-24 2011-01-12 Abbott Biotechnology Ltd. Tnf-alpha inhibitors for treating bone loss
AU2009243184B2 (en) * 2008-04-28 2015-06-04 Humanigen, Inc. Antibodies to granulocyte-macrophage colony-stimulating factor
EP3056217B1 (en) 2008-12-22 2021-06-30 The University of Melbourne Osteoarthritis treatment
KR101761324B1 (ko) 2008-12-22 2017-07-25 더 유니버시티 오브 멜버른 통증 치료
CA2759506A1 (en) 2009-04-23 2010-10-28 Theraclone Sciences, Inc. Granulocyte-macrophage colony-stimulating factor (gm-csf) neutralizing antibodies

Similar Documents

Publication Publication Date Title
JP2012512814A5 (OSRAM)
CY1119474T1 (el) Κρυσταλλικες μορφες 5-χλωρο-ν2-(2-ισοπροποξυ-5-μεθυλ-4-πιπεριδιν-4-υλ-φαινυλ)-ν4[2-(προπανο-2-σουλφονυλ)-φαινυλ]-πυριμιδιν-2,4-διαμινης
IL227113B (en) Tamper resistant solid oral dosage forms
JP2009256391A5 (OSRAM)
JP2013514381A5 (OSRAM)
JP2013014622A5 (OSRAM)
JP2011006431A5 (OSRAM)
JP2012512815A5 (OSRAM)
CN104812762A8 (en) Substituted annulated pyrimidines and triazines, and use thereof
JP2013525444A5 (OSRAM)
EP2475427A4 (en) ACTRIIB ANTAGONISTS, THEIR DOSAGE AND APPLICATIONS THEREOF
BRPI0920082A2 (pt) forma de dosagem oral de acetaminofeno/tramadol com liberação estendida.
EA201101190A1 (ru) Фармацевтическая композиция, включающая линаглиптин и необязательно ингибитор sglt2, и ее применение
HUE046557T2 (hu) Tapentadolt tartalmazó vizes gyógyszerészeti készítmény szájon át alkalmazásra
AP2010005429A0 (en) The use of solid carrier particles to improve the processability of a pharmaceutical agent.
BRPI1015996A2 (pt) composições farmacêuticas aquosas contendo complexos de borato-poliol
JP2014530840A5 (OSRAM)
DK2420223T3 (da) Vandige farmaceutiske sammensætninger med borat-polyol-komplekser
HUE052617T2 (hu) Oligoszacharid és eljárás elõállítására
LT4104824T (lt) Kompozicijos, skirtos panaudoti taikant pacientams su didele širdies ir kraujagyslių ligos rizika antsvorio ir nutukimo gydymo būdą
SI2645992T1 (sl) Trdna oralna dozirna oblika z asimetrično obliko
EP2624815B8 (en) Oral vaccine fast-dissolving dosage form using starch
JP2012136529A5 (OSRAM)
EA201200616A1 (ru) Производные 2-оксо-1-пирролидинилимидазотиадиазола
EP2695897A4 (en) NEW ANTI-RECEPTOR ANTIBODY OF IL-23 HUMAN